Literature DB >> 19925496

Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.

Z Yang1, Q Wu, K Wu, D Fan.   

Abstract

BACKGROUND: Infliximab was approved for use in ulcerative colitis in recent years. It has been debated if infliximab increases the risk of post-operative complications in patients with ulcerative colitis. AIM: To perform a meta-analysis that examines the relationship between preoperative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.
METHODS: We searched the PubMed and MEDLINE databases to identify observational studies on the impact of pre-operative infliximab use on short-term post-operative complications in ulcerative colitis. Infectious complications mainly included wound infection, sepsis and abscess, whereas non-infectious complications included intestinal obstruction, thromboembolism and gastrointestinal haemorrhage. Pooled odds ratios (ORs) were calculated for each relationship.
RESULTS: A total of 5 studies and 706 patients were included in our meta-analysis. Overall, we did not find a strong association between pre-operative treatment of infliximab and short-term infectious [OR 2.24, 95% confidence interval (CI) 0.63-7.95] or non-infectious (OR 0.85, 95% CI 0.50-1.45) post-operative complications in ulcerative colitis patients. On the contrary, we discovered that pre-operative infliximab use increased short-term total post-operative complications (OR 1.80, 95% CI 1.12-2.87).
CONCLUSIONS: Pre-operative infliximab use increased the risk of short-term post-operative complications. Subgroup analysis is underpowered to assess the nature of these complications but shows a trend towards increased post-operative infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925496     DOI: 10.1111/j.1365-2036.2009.04204.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  33 in total

1.  Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan.

Authors:  Hideaki Kimura; Kenichi Takahashi; Kitaro Futami; Hiroki Ikeuchi; Kenji Tatsumi; Kazuhiro Watanabe; Kiyoshi Maeda; Yusuke Watadani; Riichiro Nezu; Hitoshi Kameyama; Sayumi Nakao; Kiyotaka Kurachi; Masayuki Hotokezaka; Koki Otsuka; Toshiaki Watanabe; Heita Ozawa
Journal:  Surg Today       Date:  2015-10-14       Impact factor: 2.549

Review 2.  Surgical treatment of ulcerative colitis in the biologic therapy era.

Authors:  Alberto Biondi; Marco Zoccali; Stefano Costa; Albert Troci; Ettore Contessini-Avesani; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

3.  Impact of a best clinical therapy management on surgery for ulcerative colitis.

Authors:  R F Leal; M de Lourdes Setsuko Ayrizono; P de Sene Portel Oliveira; J J Fagundes; C S R Coy
Journal:  Tech Coloproctol       Date:  2012-05-23       Impact factor: 3.781

Review 4.  Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.

Authors:  G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-01-25       Impact factor: 3.781

Review 5.  [Refractory inflammatory bowel disease: surgical challenges].

Authors:  H J Buhr; A J Kroesen
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

6.  Surgical risks in patients on inflammatory bowel disease medications.

Authors:  Bret A Lashner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

Review 7.  Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.

Authors:  Brijen Shah; Lloyd Mayer
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

8.  Recent advances in the management of distal ulcerative colitis.

Authors:  Ioannis E Koutroubakis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-04-06

Review 9.  Inflammatory bowel disease surgery in the biologic era.

Authors:  Linda Ferrari; Mukta K Krane; Alessandro Fichera
Journal:  World J Gastrointest Surg       Date:  2016-05-27

10.  Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.

Authors:  Ryan Nelson; Chuanhong Liao; Alessandro Fichera; David T Rubin; Joel Pekow
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.